[{"orgOrder":0,"company":"Mologen AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"MGN1601","moa":"Tumor-associated antigens","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mologen AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mologen AG \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mologen AG \/ Undisclosed"},{"orgOrder":0,"company":"Mologen AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"MGN1703","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Mologen AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mologen AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mologen AG \/ Undisclosed"},{"orgOrder":0,"company":"Mologen AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2010","type":"Inapplicable","leadProduct":"MGN1703","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Mologen AG","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mologen AG \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Mologen AG \/ Undisclosed"},{"orgOrder":0,"company":"Mologen AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Oligonucleotide","year":"2014","type":"Inapplicable","leadProduct":"MGN1703","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Mologen AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Mologen AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mologen AG \/ Undisclosed"},{"orgOrder":0,"company":"Mologen AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Oligonucleotide","year":"2013","type":"Inapplicable","leadProduct":"MGN1703","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Mologen AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mologen AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Mologen AG \/ Undisclosed"},{"orgOrder":0,"company":"Mologen AG","sponsor":"Mologen AG","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2016","type":"Inapplicable","leadProduct":"MGN1703","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Mologen AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mologen AG \/ Mologen AG","highestDevelopmentStatusID":"6","companyTruncated":"Mologen AG \/ Mologen AG"}]